Vertex will pay CRISPR Therapeutics $100m up-front for non-exclusive rights to its technology with the goal of developing a certain type of therapy for diabetes.
Boston-based company, Vertex, has signed a deal to use Arbor Biotechnologies’ CRISPR gene-editing technology to develop novel cell therapies for the treatment of serious diseases.
Vertex is set to acquire Semma, which is developing a stem cell curative treatment for type 1 diabetes and expects the deal to ‘rapidly advance’ its potential therapy.
Vertex agrees to acquire Exonics and to expand its collaboration with CRISPR Therapeutics, which sees it invest $420m in upfront payments to develop its position in gene therapy.